Phellilane L, Sesquiterpene Metabolite of <i>Phellinus linteus</i>: Isolation, Structure Elucidation, and Asymmetric Total Synthesis

A new cyclopropane-containing sesquiterpenoid, phellilane L (<b>1</b>), was isolated from the medicinal mushroom <i>Phellinus linteus</i> (“Meshimakobu” in Japanese), a member of the Hymenochaetaceae family and a well-known fungus that is widely used in East Asia. The planar structure of <b>1</b> was determined on the basis of spectroscopic analysis. The authors achieved the first total synthesis of <b>1</b>. Our protecting group-free synthesis features a highly stereoselective one-pot synthesis involving an intermolecular alkylation/cyclization/lactonization strategy for construction of the key cyclopropane-γ-lactone intermediate. Additionally, our synthesis determined the absolute configuration of phellilane L (<b>1</b>)

Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from <i>Stellera chamaejasme</i>

Five novel tigliane-type diterpenes, stelleracins A–E (<b>3</b>–<b>7</b>), a novel flavanone dimer, chamaeflavone A (<b>8</b>), and six known compounds were isolated from the roots of <i>Stellera chamaejasme</i>. Their structures were elucidated by extensive spectroscopic analyses. The isolated compounds were evaluated for anti-HIV activity in MT4 cells. New compounds <b>3</b>–<b>5</b> showed potent anti-HIV activity (EC₉₀ 0.00056–0.0068 μM) and relatively low or no cytotoxicity (IC₅₀ 4.4–17.2 μM). These new compounds represent promising new leads for development into anti-AIDS clinical trial candidates

Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from <i>Stellera chamaejasme</i>

Five novel tigliane-type diterpenes, stelleracins A–E (<b>3</b>–<b>7</b>), a novel flavanone dimer, chamaeflavone A (<b>8</b>), and six known compounds were isolated from the roots of <i>Stellera chamaejasme</i>. Their structures were elucidated by extensive spectroscopic analyses. The isolated compounds were evaluated for anti-HIV activity in MT4 cells. New compounds <b>3</b>–<b>5</b> showed potent anti-HIV activity (EC₉₀ 0.00056–0.0068 μM) and relatively low or no cytotoxicity (IC₅₀ 4.4–17.2 μM). These new compounds represent promising new leads for development into anti-AIDS clinical trial candidates